Scientific Founders

Dr. David Neil Hayes, MD MPH MS
Dr. Hayes is a founder and director at GeneCentric Therapeutics. Dr. Hayes is an Associate Professor in the Department of Medicine, Division of Hematology/Oncology at the Lineberger Comprehensive Cancer Center of the University of North Carolina at Chapel Hill. Dr. Hayes research brings together researchers with intersecting interests in multidisciplinary clinical care, clinical trials, translational cancer research, and model systems of cancer with a focus on aerodigestive tumors. In the lab, he uses genetic and genomic techniques to characterize molecular alterations of cancer for the purposes of describing new patterns of clinically relevant disease. This work includes biomarker discovery and validation, and includes germline and somatic variations in DNA structure and sequence, as well as patterns of gene expression, protein expression, and the influence of environmental factors. He has extensive expertise in bioininformatics and its application to the analysis of large databases of microarray data and the integration of multiple data sets. He is the Director of Clinical Bioinformatics at the Lineberger Cancer Center. Dr. Hayes received his BS from Davidson College, his MD from the University of North Carolina at Chapel Hill, his MPH from the Harvard School of Public Health and his MS from Tufts New England Medical Center. He completed his residency training in Internal Medicine at the Boston University School of Medicine, and additional fellowships in Hematology/Oncology at Tufts New England Medical Center and the Dana Farber Cancer Institute.


Dr. Charles M. Perou, PhD
Dr. Perou is a founder and director at GeneCentric Therapeutics. Dr. Perou is the May Goldman Shaw Distinguished Professor of Molecular Oncology, Professor of Genetics, and Pathology & Laboratory Medicine and Member of the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Dr Perou’s research crosses the disciplines of genomics, cancer research, bioinformatics and clinical care. His major contribution to the field has been in the characterization of the diversity of tumors, beginning first in breast cancer and more recently extending to lung cancer. Dr. Perou has authored more than 150 peer reviewed articles. He earned his BA in Biology from Bates College, his PhD in Cell Biology from the University of Utah, and performed his postdoctoral work in the laboratory of David Botstein (then at Stanford University). He has been a faculty member at UNC since 2000. Additionally, he was the recipient of the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, and recipient of the 2011 Danaher Scientific and Medical Award, a Susan G Komen Award for Scientific Distinction.


To view the management team click here

To view the drug development team click here.

To view the board of directors click here